Tumor antioxidative enzymes and hypoxic microenvironment

The 'Tumor antioxidative enzymes and hypoxic microenvironment' refers to a coupled biological system that enables solid tumors to survive and proliferate under conditions of low oxygen and high metabolic stress. Hypoxia, primarily regulated by the transcription factor Hypoxia-Inducible Factor 1-alpha (HIF-1α), triggers a metabolic shift that increases the production of reactive oxygen species (ROS) (Semenza, 2012, PMID: 22817877). To survive this oxidative pressure, cancer cells upregulate a network of antioxidative enzymes, such as Superoxide Dismutase (SOD), Catalase, and the Glutathione/Thioredoxin systems, which maintain redox homeostasis (Gorrini et al., 2013, PMID: 23470572). This adaptation not only promotes tumor growth and metastasis but also confers resistance to therapies like radiation and chemotherapy that rely on ROS-mediated cell death (Harris, 2002, PMID: 12154401). Therapeutic strategies targeting this axis include hypoxia-activated prodrugs (HAPs) like Tirapazamine and small-molecule inhibitors of antioxidant enzymes, which aim to selectively induce lethal oxidative stress within the tumor microenvironment (Wilson & Hay, 2011, PMID: 21350488). Overall, this system represents a critical vulnerability in solid tumors that is currently being explored through various redox-modulating and hypoxia-targeted clinical approaches.

Other names

Tumor redox-hypoxia axisAntioxidant defense system in tumor hypoxiaHypoxia-ROS signaling networkTumor oxidative stress response

Inhibition of antioxidant enzymes (e.g., SOD, TrxR) to induce oxidative stress; Bioreductive activation of hypoxia-activated prodrugs (HAPs); Inhibition of HIF-1α transcriptional activity.